F-STAR THERAPEUTICS, INC.
Eddeva B920
Babraham Research Campus
Cambridge, CB22 3AT, United Kingdom
April 7, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Abby Adams
| RE: | F-star Therapeutics, Inc. |
Registration Statement on Form S-3
Filed March 31, 2021
File No. 333-254884
Acceleration Request
Dear Ms. Adams:
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of F-star Therapeutics, Inc. (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Friday, April 9, 2021, at 5:00 p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Megan Gates or William Hicks of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 542-6000, with any comments or questions regarding the Registration Statement.
| Very truly yours, |
| F-STAR THERAPEUTICS, INC. |
/s/ Darlene Deptula-Hicks |
| Darlene Deptula-Hicks |
| Chief Financial Officer |
| cc: | Megan N. Gates, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
William C. Hicks, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
